scholarly journals Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma

2017 ◽  
Vol 98 (3) ◽  
pp. 289-295 ◽  
Author(s):  
Massimo Offidani ◽  
Laura Corvatta ◽  
Sara Bringhen ◽  
Silvia Gentili ◽  
Rossella Troia ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Retrospective Study ◽  
Salvage Therapy ◽  
Patient Population ◽  
Large Patient ◽  
Large Patient Population ◽  
First Relapse

Treatment of smell loss with systemic methylprednisolone

2012 ◽  
Vol 50 (3) ◽  
pp. 284-289
Author(s):  
V.A. Schriever ◽  
C. Merkonidis ◽  
N. Gupta ◽  
C. Hummel ◽  
T. Hummel
Keyword(s):  
Patient Population ◽  
Current Approach ◽  
Olfactory Dysfunction ◽  
Systemic Corticosteroids ◽  
Large Patient ◽  
Before And After ◽  
Large Patient Population ◽  
Randomized Control ◽  
Smell Loss ◽  
Tdi Score

Background and aim: Olfactory dysfunction is a common complaint in a large number of people. As the aetiologies of olfactory dysfunction vary greatly so do the treatment approaches. The aim of this retrospective study was to evaluate treatment with systemic corticosteroids, particularly focusing on its effectiveness on the different olfactory dysfunction aetiologies. Although a prospective randomized control trail is preferred for such an investigation, using the current approach, we were able to test a very large patient population. Material and methods: A total of 425 patients with olfactory dysfunction were treated with systemic corticosteroids for 14 days. Olfactory performance was measured using the `Sniffin` Sticks` battery before and after the treatment. Results: The treatment with systemic corticosteroids significantly increased the performance on the TDI score and on each of the three subtests; threshold, discrimination and identification. In 26.6% of the patients improvement of more than six points of the TDI score was observed. The treatment proved to be more effective in patients with sinunasal olfactory dysfunction, where this percentage increased to 36.7, compared to other aetiologies. In addition, the increase in olfactory function was negatively correlated with the TDI score before the treatment. Conclusion: This study confirms the effectiveness of systemic corticosteroids on olfactory dysfunction in a large patient population. Specifically, the results show that treatment is: (a) more effective in patients with sinunasal than in patients with idiopathic olfactory dysfunction, (b) most effective in patients with sinunasal disease with nasal polyps, and (c), at best, effective in half of the patients. The current study may provide help in counselling patients.

Outcomes of Flap Lift Laser In Situ Keratomileusis Enhancements in a Large Patient Population

Cornea ◽  
2019 ◽  
Vol 38 (12) ◽  
pp. 1531-1535
Author(s):  
Julio Ortega-Usobiaga ◽  
Julio Baviera-Sabater ◽  
Fernando Llovet-Osuna ◽  
Félix González-López ◽  
Rafael Bilbao-Calabuig ◽  
...  
Keyword(s):  
Patient Population ◽  
Laser In Situ Keratomileusis ◽  
Large Patient ◽  
Large Patient Population

Clinical Performance of the St. Jude Medical Riata Defibrillation Lead in a Large Patient Population

2010 ◽  
Vol 21 (5) ◽  
pp. 551-556 ◽  
Author(s):  
JAMES G. PORTERFIELD ◽  
LINDA M. PORTERFIELD ◽  
KARL H. KUCK ◽  
RAFFAELE CORBISIERO ◽  
STEVEN M. GREENBERG ◽  
...  
Keyword(s):  
Patient Population ◽  
Clinical Performance ◽  
Jude Medical ◽  
Large Patient ◽  
Large Patient Population

scholarly journals Visit to Abbasiah Hospital, Egypt

1997 ◽  
Vol 21 (1) ◽  
pp. 45-46
Author(s):  
Rafeek Mahmood ◽  
Chris Thompson ◽  
John Robertson
Keyword(s):  
Psychiatric Hospital ◽  
Royal College ◽  
Patient Population ◽  
Medical Director ◽  
Large Patient ◽  
Regional Meeting ◽  
Large Patient Population

At a Regional meeting of Members and Fellows of the Royal College of Psychiatrists, held in Cairo in April 1994, a strong initiative to promote Abbasiah Psychiatric Hospital as a teaching centre was put forward. The President, Registrar and Dean made a preliminary visit to the hospital and met with Dr S. Al-Kott, the Medical Director, and agreed to offer assistance on behalf of the Royal College of Psychiatrists. It was anticipated that Abbasiah would benefit through improved recruitment into medical and nursing posts, and by the injection of renewed interest in its large patient population.

Comparison of lenalidomide plus dexamethasone therapy used at first relapse versus later salvage therapy in relapsed or refractory multiple myeloma patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 8594-8594
Author(s):  
E. A. Stadtmauer ◽  
D. M. Weber ◽  
R. Nieszvizky ◽  
A. Belch ◽  
H. M. Prince ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Salvage Therapy ◽  
Response Rate ◽  
Early Stage ◽  
Progression Free Survival ◽  
Phase Iii ◽  
Duration Of Treatment ◽  
Refractory Multiple Myeloma ◽  
Prior Therapy ◽  
First Relapse

8594 Background: The benefit of initiating lenalidomide plus dexamethasone at first relapsed was evaluated in this subset analysis from phase III studies in patients with relapsed or refractory multiple myeloma (MM). Methods: Patients from the randomized, multicenter clinical trials MM-009 and MM-010 who had received at least 1 prior treatment and were not resistant to dexamethasone were treated with lenalidomide (25 mg daily for 21 days of every 28 day cycle) plus dexamethasone (40 mg on days 1–4, 9–12, and 17–20 every 28 days for 4 months, then 40 mg on days 1–4 every cycle thereafter until disease progression or intolerance), or dexamethasone (same dose and schedule) plus placebo. Baseline characteristics such as age, sex, ECOG score, and baseline β2-microglobulin levels between the 2 patient groups were similar, however, median time from diagnosis and prior therapy were statistically different. Results: Multivariate analysis showed that more prior therapies is associated with shorter time-to-progression (TTP). Patients who received 1 prior therapy demonstrated a significant improvement in outcomes such as TTP, progression-free survival (PFS), overall response rate (ORR), complete response/very good partial response rate (CR/VGPR), median duration of treatment and overall survival (OS) after first relapse compared with those who received ≥ 2 prior therapies ( Table ). Toxicity, rate of dose reduction, or treatment discontinuation in the cohort with 1 prior therapy did not increase, despite longer treatment. Conclusions: When used at first relapse compared with salvage therapy, lenalidomide plus dexamethasone treatment resulted in significantly prolonged TTP, PFS, and OS, and an improved quality of response. Lenalidomide plus dexamethasone should be considered at an early stage of therapy for patients with MM. [Table: see text] [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document